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Remote ischemic preconditioning is a physiologic mechanism in mammalian species whereby brief exposure to nonlethal
ischemia in one tissue confers protection against a prolonged ischemic insult in a distant tissue. first described almost 15
years ago, it has been slow to translate into clinical practice. several clinical trials have recently reported that remote
ischemic preconditioning reduces myocardial injury after major cardiovascular surgery. in addition, a randomized trial in
patients undergoing open abdominal aortic aneurysm repair reported a significant reduction in perioperative myocardial
infarctions. remote ischemic preconditioning is easily performed and likely to prove highly cost-effective. large-scale trials
of the technique are warranted in patients undergoing major vascular surgery. (J Vasc Surg 2009;49:240-3.)Patients undergoing major vascular surgery represent a
high-risk surgical population because of the presence of
generalized arterial disease. In particular, vascular pa-
tients are susceptible to ischemia–reperfusion injury (IRI),
which is an integral part of most vascular procedures.
Perioperative death and major morbidity rates for patients
undergoing index vascular procedures such as open and
endovascular aneurysm repair, carotid endarterectomy, and
infrainguinal bypass range from about 3% to 25%.1-3 An
ageing population means that the demand for major vascu-
lar interventions is steadily increasing, and by 2030, it is
anticipated that 1 to 2 million such procedures will be
performed in the United States, resulting in about 18,000
deaths.4 In addition, large numbers of patients will have
complications that may have adverse effects, ranging from
an extra day in hospital to life-long hemodialysis depen-
dence.
Multiple mechanisms produce perioperative complica-
tions. For example, during open aneurysm repair, renal
injury may result from a low-flow state in the renal vascu-
lature due to systemic hemodynamic instability, a no-flow
state arising from direct interference with renal blood flow
due to suprarenal or juxtarenal clamping, or indirectly due
to the release of toxic metabolites into the general circula-
tion when the lower limbs are reperfused.5 Similarly, myo-
cardial injury may result from a low-flow state across a
hemodynamically significant coronary artery stenosis, fis-
suring of a plaque producing acute thrombosis, or excessive
demands on the myocardium exceeding the compensatory
ability of diseased coronary vasculature to supply adequate
oxygen to the cells.6
Most strategies to reduce complications target a specific
etiological mechanism. Attempts to reduce perioperative
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240cardiac morbidity by preoperative cardiac intervention have
failed to produce the expected results.7 Perioperative
-blockade attempts to reduce myocardial injury by limit-
ing myocardial oxygen demand,8 aspirin may reduce the
risk of coronary thrombosis by platelet inhibition,9 and
statins reduce the risk of plaque rupture.10 These strategies
will only ever produce small incremental improvements in
outcome because they only address single etiologic mech-
anisms. Thus, although aspirin will reduce the risk of
thrombosis and statins will stabilize plaques and reduce the
risk of plaque fissuring, neither will protect against a hemo-
dynamic myocardial injury due to low flow across a signif-
icant but otherwise asymptomatic stenosis.
IRI is the final common pathway that leads to end-
organ damage regardless of the mechanism that led to
ischemia in the first place.5,11 If the cells in delicate end
organs such as the heart, kidneys, and brain could be
induced to convert to an ischemia–reperfusion resistant
phenotype, this would provide protection against the dev-
astating effects of IRI. Moreover, because the protection
does not target a specific etiologic mechanism, this end
organ protection could produce a much greater incremen-
tal reduction in morbidity than single mechanism strategies
such as aspirin and statin use. Such a mechanism was
identified in mammalian cells20 years ago, and emerging
clinical evidence suggests that it may significantly reduce
morbidity after major vascular surgery.
ISCHEMIC PRECONDITIONING
About 25 years ago, it was thought that exposure to
successive brief periods of ischemia had a cumulative effect
leading to tissue necrosis and organ infarction.12 This pre-
vailing dogma was challenged by several experiments in
canine models of myocardial ischemia. Cardiac myocytes
exposed to 10 minutes of ischemia sustained intracellular
adenosine triphosphate (ATP) and adenine nucleotide de-
pletion, as expected. However, if the same myocytes were
exposed to a further 10-minute ischemic insult after 20
minutes of reperfusion, no further depletion occurred.
These observations suggested that reperfusion after a brief
period of ischemia somehow triggered a mechanism that
JOURNAL OF VASCULAR SURGERY
Volume 49, Number 1 Walsh et al 241prevented further loss of intracellular ATP during subse-
quent repeated ischemic insults.13
The same group hypothesized that multiple brief isch-
emic episodes might provide some protection for the heart
against damage due to a subsequent prolonged ischemic
insult. One group of dogs underwent a single 40-minute
circumflex occlusion. A second group underwent four
5-minute-long circumflex occlusions, separated by
5-minute periods of reperfusion, followed by a 40-minute
occlusion. The second group had significantly smaller areas
of infarcted myocardium on subsequent histologic study.
This suggested that brief periods of intermittent ischemia
provide protection against a subsequent ischemic insult.
However, the effect disappeared when the animals were
subjected to 3 hours of occlusion instead of 40 minutes, so
the protection was limited to significant but moderate
episodes of ischemia.14
Subsequent work in patients undergoing coronary ar-
tery bypass graft surgery confirmed that the mechanism,
known as ischemic preconditioning (IPC), is preserved in
humans.15 Moreover, it is not confined to cardiac cells: A
range of tissues have been successfully preconditioned in
animal models, including skeletal muscle,16,17 liver,18,19
kidney,20 and brain.21 However, triggering IPC required
direct interference with the blood supplies of the target
tissues. It was concluded that this factor limited its clinical
utility to scenarios where the blood supply is readily acces-
sible, such as open heart surgery. Moreover, this depen-
dence on direct the interference with the blood supply
implied that IPC could only provide single-organ protec-
tion in most procedures, for example, the myocardium can
be protected during open heart surgery but not the kid-
neys. This resulted in a flurry of small clinical trials in cardiac
surgery, but little interest in other surgical fields.
REMOTE ISCHEMIC PRECONDITIONING
Analysis of canine models of cardiac IPC revealed that
the infarction area in preconditioned hearts tended to
increase in proportion to the left ventricle area at risk and,
furthermore, that the distance between the edge of the
infarct and the margin of the risk area increased as the risk
region decreased. Conversely, this lateral distance remained
the same in control hearts as the area at risk increased.22
These observations were formulated into a mathematic
model that suggested that a trigger generated in nonisch-
emic tissue may contribute to the myocardial protection
produced by conventional, direct IPC.23
The model implied that ischemia induced in one coro-
nary vascular bed protects the myocardium in another
coronary vascular bed. This hypothesis was confirmed in
the canine heart, where circumflex territory ischemia pro-
tected the left anterior descending artery territory against a
subsequent prolonged ischemic insult.24 Thus, ischemia in
one vascular bed protects tissue in another vascular bed,
albeit in the same organ.
Gho et al25 hypothesized from this observation that
ischemia in a distant vascular bed or organ would protect
the heart. They found that mesenteric ischemia reducedmyocardial infarction size.25 Renal ischemia produced sim-
ilar results.26 The kidneys and to a lesser extent the intestine
are vulnerable to damage from even brief periods of isch-
emia. The blood supply of these organs is also inaccessible
in many clinical scenarios, rendering them unfeasible can-
didates as the remote stimulus for cardioprotection. Skele-
tal muscle, on the other hand, is relatively resistant to
damage from ischemia. Transient lower limb ischemia in
animal models reduces myocardial infarction size27 and
reperfusion tachyarrhythmias.28
Skeletal muscle ischemia can be induced simply by the
application of an inflatable cuff or tourniquet, with a neg-
ligible risk of iatrogenic injury. It can be performed in
patients undergoing any type of operation. The protection
is not organ specific, so a patient receives simultaneous
protection against IRI in any organ. Thus, remote IPC
(RIPC) has the potential to significantly reduce morbidity
and mortality in any field of surgery. To date, small clinical
trials have been conducted in patients undergoing open
heart surgery and open abdominal aortic aneurysm (AAA)
repair. The initial results have been encouraging.
MECHANISMS OF RIPC
Huge efforts have been made to elucidate the mecha-
nistic pathways responsible for RIPC, but the details remain
unclear. There may be some overlap with the mechanisms
of ischemic preconditioning and also postconditioning.
Hausenloy and Yellon29 recently published a thorough
review of the current data on putative mechanistic path-
ways. Briefly, at present, there are three theories regarding
the mechanism:
● The neural theory proposes that the remote organ
releases endogenous substances such as adenosine and
bradykinin that activate a local afferent neural pathway;
this, in turn, activates an efferent neural pathway that
triggers end organ protection.
● The humoral theory suggests that the remote tissue
releases adenosine, bradykinin, or some other sub-
stance into the bloodstream, which carries it to the end
organ where it binds to receptors and triggers the
intracellular pathways that mediate protection.
● The inflammatory suppression theory suggests that
remote organ ischemia suppresses inflammation and
apoptosis in cells, reducing the systemic inflammatory
response.29
CLINICAL UTILITY OF RIPC
RIPC could be of considerable value in major vascular
surgery. Ischemia–reperfusion injury is an inherent compo-
nent of arterial surgery. A single method to protect all
vulnerable organs against this ischemia–reperfusion injury
would be of great value. RIPC has the added attraction that
it can be achieved easily with readily available equipment in
all vascular units, without any capital outlay or ongoing
costs. Thus, it could be an extremely cost-effective means of
reducing perioperative complications.
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surgery. Cheung et al30 randomized 37 children undergo-
ing open heart surgery for a variety of cardiac problems to
receive four 5-minute cycles of lower limb ischemia as a
RIPC stimulus about 5 to 10 minutes before the initiation
of cardiopulmonary bypass.30 The 17 RIPC patients had
significantly less myocardial damage, as indicated by lower
concentrations of serum troponin I. That said, both groups
exhibited a similar pattern of troponin elevations, with an
immediate rise in the first few hours after surgery, tapering
off by 24 hours; thus, RIPC reduced but did not eliminate
myocardial injury. RIPC also produced a statistically signif-
icant reduction in inotrope requirements, although the
actual reduction was only on the order of 2 to 3 gs/kg/
min.30 Despite the apparent reduction in myocardial dam-
age and inotrope requirements, the length of the postop-
erative critical care stay was unchanged, with the RIPC
group requiring a mean stay of 54.2  40.7 hours com-
pared with 39.5  25.7 hours for the control group.30
Hausenloy et al31 randomized 57 adults undergoing
coronary artery bypass grafting to receive RIPC or not. This
time the RIPC stimulus comprised three cycles of 5 min-
utes of ischemia induced by inflating a blood pressure cuff
to 200 mm Hg, followed by 5 minutes reperfusion in the
upper limb. RIPC was performed in 27 patients after in-
duction of anesthesia. These patients had a significant re-
duction in serial postoperative serum troponin T levels
compared with the 30 non-RIPC controls. However, no
data were provided on clinical end points such as hospital
stay or death because this small trial was underpowered to
detect any significant differences.31
Our unit has conducted the largest clinical trial of RIPC
to date, to our knowledge, in the setting of open AAA
repair.32 Eighty-two patients undergoing elective open
AAA repair were randomized to receive RIPC or not. The
RIPC was triggered by clamping each common iliac artery
sequentially for 10 minutes, followed by 10 minutes of
reperfusion. Cross clamping was performed only once the
second leg had been allowed to reperfuse for 10 minutes.
No lower limb ischemia developed that required interven-
tion. Significant troponin elevations (0.2 ng/mL) oc-
curred in 15 of 42 control patients (36%) compared with
three of 41 preconditioning patients (7%), a significant
reduction (P  .002). Postoperative myocardial injury
(serum troponin 1.5 ng/mL) and infarction was signifi-
cantly lower in the RIPC group (2 of 41 patients vs 13 of
42; P  .002). The duration of critical care stay was
significantly reduced from a mean of 2  2.3 days in the
control group to 1.0  0.2 days for RIPC patients (P 
.007). Although the trial was relatively small, the results
were very encouraging and suggest that RIPC could signif-
icantly reduce the complication burden of major vascular
surgery.
RIPC could be of benefit in other major vascular pro-
cedures. Although less invasive than open aneurysm sur-
gery, endovascular aneurysm repair is still associated with
significant mortality and major morbidity of about 4% in
randomized series, rising to 17% in nonrandomized se-ries.33 Recent data from a cohort of almost 10,000 Medi-
care patients undergoing carotid endarterectomy in the
United States suggests that the perioperative mortality is
about 1%, the perioperative stroke rate is about 3.3%, and a
major cardiac complication (myocardial infarction, unsta-
ble angina, pulmonary edema or ventricular tachycardia)
develops in 3.9%.34
A cerebral preconditioning effect has been observed in
patients undergoing neurovascular surgery.35 More re-
cently, Faries et al36 described an apparent preconditioning
effect obtained during carotid artery stenting. Neurologic
deficits developed in 10 patients when their internal carotid
artery was occluded with a balloon. The symptoms resolved
10 minutes of balloon deflation. Subsequent reinflation
to allow stenting was not associated with any recurrence of
the neurologic symptoms, suggesting that the area of brain
at risk was now protected against ischemic injury, at least
temporarily.36 RIPC could significantly reduce the compli-
cation burden arising from both endovascular aneurysm
repair and carotid endarterectomy.
CONCLUSIONS
Several randomized trials demonstrate that RIPC can
reduce cardiac injury. Although some patients will always
sustain severe ischemic insults that RIPC cannot amelio-
rate, the technique has the capacity to significantly reduce a
variety of complications after major vascular surgery. The
beneficial effects of RIPC can be achieved by the modifica-
tion of existing surgical techniques and requires no expen-
sive drugs or equipment. Further large-scale clinical studies
are required to establish the value of RIPC in vascular
surgery.
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